|Bid||0.00 x 1000|
|Ask||2.50 x 3200|
|Day's Range||1.5200 - 1.6600|
|52 Week Range||0.6700 - 2.8600|
|Beta (3Y Monthly)||1.35|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 14, 2019 - Mar 18, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||1.85|
Genesis Healthcare (GEN) delivered earnings and revenue surprises of 5.88% and 0.44%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Kennett Square, Pennsylvania-based company said it had a loss of 57 cents. Losses, adjusted for asset impairment costs, were 32 cents per share. The operator of nursing homes ...
Genesis Healthcare (GEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Genesis HealthCare (GEN) (Genesis or the Company), one of the nation’s largest providers of post-acute care, today announced that it expects to release its third quarter 2018 results after the market closes on Wednesday, November 7, 2018. To participate in the call, interested parties may dial (855) 849-2198 or listen to a live webcast and replay of the call on the Company’s website at http://www.genesishcc.com/investor-relations. Genesis HealthCare (GEN) is a holding company with subsidiaries that, on a combined basis, comprise one of the nation's largest post-acute care providers with more than 400 skilled nursing facilities and assisted/senior living communities in 30 states nationwide.
Eddie Lampert made billions taking risks despite a chorus of naysayers. But his big bet on Sears Holdings ran headlong into the unforgiving economics of the modern retailing business.
Bankrupt Preferred Care Inc. will hand over operations of five nursing homes in New Mexico to another health-care company after a bankruptcy judge approved that transfer Tuesday. Inc., a Pennsylvania company that operates more than 450 nursing homes across the country. Inc., which made agreements with Preferred Care to operate them.
NEW YORK, Oct. 17, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Upon the complete exit from the state of Texas, Genesis estimates these transactions will result in the reduction of approximately $94 million of indebtedness. “We are constantly reviewing our portfolio with an emphasis on divesting underperforming assets or assets in non-strategic markets,” noted George V. Hager, Jr., Chief Executive Officer of Genesis. “This deleveraging transaction will allow for additional focus on our core markets and will strengthen our overall portfolio,” noted Hager.
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Over the last month, growth of ETFs holding GEN is favorable, with net inflows of $3.46 billion.
NEW YORK, NY / ACCESSWIRE / August 8, 2018 / Genesis Healthcare Inc Class A (NYSE: GEN ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 8, 2018 at 8:30:00 AM Eastern ...
Genesis Healthcare (GEN) delivered earnings and revenue surprises of 34.62% and -2.58%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
The Kennett Square, Pennsylvania-based company said it had a loss of 39 cents per share. Losses, adjusted for asset impairment costs, were 17 cents per share. The operator of nursing homes and senior living ...
On Tuesday, July 17, 2018, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged higher at the closing bell. Six out of nine sectors ended Tuesday's trading session in bullish territories. Taking into consideration yesterday's market sentiment, WallStEquities.com assessed the following Healthcare equities this morning: Brookdale Senior Living Inc. (NYSE: BKD), Envision Healthcare Corp. (NYSE: EVHC), Genesis Healthcare Inc. (NYSE: GEN), and Acceleron Pharma Inc. (NASDAQ: XLRN).
DNA testing at home in Japan is starting to gain traction as more people age and seek answers about their risks for diseases. The market for consumer genetic tests is poised to reach 6.6 billion yen ($58 million) in sales by 2022, up from 4.3 billion yen last year, according to Fuji Chimera Research Institute. The sector is dominated by two local companies, Genesis Healthcare Co. and Genequest Inc. For 5,000 yen to 30,000 yen, customers can send off a cheek swab to find out their propensities for alcohol intolerance and allergies, to risks of diabetes and strokes.